Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 25, Issue , 2014, Pages iii21-iii26

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB; PLACEBO; REGORAFENIB; SUNITINIB;

ADJUVANT THERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOSCOPIC BIOPSY; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; KIT GENE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STOMACH SURGERY; TREATMENT DURATION; TREATMENT RESPONSE; GASTROINTESTINAL STROMAL TUMORS; HEALTH CARE PLANNING; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; STANDARDS;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM STAGING; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84911480554     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu255     Document Type: Article

References (41)

1. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence clinical course, and prognostication in the pre-imatinib mesylate era-a population based study in western Sweden. Cancer 2005; 103: 821-829.
2. Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23: 15-34.
3. Zhang L, Smyrk TC, Young WF, Jr et al. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 2010; 34: 53-64.
4. Pasini B, McWhinney SR, Bei T et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008; 16: 79-88.
5. Gaal J, Stratakis CA, Carney JA et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 2011; 24: 147-151.
6. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30: 90-96.
7. Rubin BP, Blanke CD, Demetri GD et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med 2010; 134: 165-170.
8. Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57: 259-270.
9. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478.
10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.
11. Gold JS, Gönen M, Gutierrez A et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-1052.
12. Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-274.
13. Ohtani H, Maeda K, Noda E et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor. Anticancer Res 2013; 33: 5031-5041.
14. Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265-1272.
15. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
16. Gronchi A, Judson I, Nishida T et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer 2009; 45: 1103-1106.
17. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 2006; 42: 1093-1103.
18. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
19. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
20. Hohenberger P, Ronellenfitsch U, Oladeji O et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97: 1854-1859.
21. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42-47.
22. Bauer S, Rutkowski P, Hohenberger P et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib-analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 2014; 40: 412-419.
23. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate forpatients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
24. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
25. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatininb: randomized trial. Lancet 2004; 364: 1127-1134.
26. Zalcberg JR, Verveij J, Casali PG et al. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
27. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 2010; 28: 1247-1253.
28. Le Cesne A, Ray-Coquard I, Bui BN et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors after 3 years of treatment: an openlabel multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-949.
29. Demetri GD, Wang Y, Wehrle E et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141-3147.
30. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-2331.
31. Wang D, Zhang Q, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012; 19: 1074-1080.
32. Mussi C, Ronellenfitsch U, Jakob J et al. Post-imatinib surgery in advanced/ metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403-408.
33. Du CY, Zhou Y, Song C et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer 2014; 50: 1772-1778.
34. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
35. George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumor after imatinib failure. Eur J Cancer 2009; 45: 1959-1968.
36. Demetri GD, Reichardt P, Kang YK et al. on behalf of all GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302.
37. Kang YK, Ryu MH, Yoo C et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14: 1175-1182.
38. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
39. Le Cesne A, Van Glabbeke M, Verweij J et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27: 3969-3974.
40. Shankar S, van Sonnenberg E, Desai J et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235: 892-898.
41. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.